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Human embryonic stem cells
regularly hit the headlines in
countries like Germany and the
United States, where researchers
are struggling for more permissive
regulations, while religious and
‘pro-life’ groups try to achieve
wide-ranging bans of embryo
research. In Germany, for instance,
any research that involves
sacrificing early stage human
embryos is illegal, and stem cells
can only be imported with a
specific licence from a national
ethics council (Curr. Biol. 13, R937).
In the US, the federal ban on state
funding for institutes involved with
stem cell research is increasingly
seen as holding back research.
Californian voters are soon to
decide on a possible investment of
$3 billion into regenerative
medicine that would fly in the face
of federal policy. Meanwhile, stem
cell news in the UK is coming thick
and fast, but here it is usually good
news for researchers. Institutes are
being opened, grants are being
allocated specifically for stem cell
research, and new human
embryonic stem cell lines are being
created. 
The University of Cambridge
has been in the spotlight of stem
cell research since 2001, when it
managed to lure Roger Pedersen
across the Atlantic, who had been
frustrated by the restrictive policy
of the US government. On June 21
this year, the university and the
Medical Research Council (MRC)
announced the foundation of a
dedicated stem cell institute,
backed by a total funding of over
16 million pounds. Three directors
will lead the areas of stem cell
medicine (Pedersen), genetics
(Azim Surani) and biology (yet to
be recruited), supported by
around 20 group leaders covering
virtually every aspect of stem cell
research. 
Arch-rival Oxford does not have
a dedicated centre yet, but
research is sprouting in many
laboratories, aided by several
project grants out of the
£40 million cross-discipline
support that the government
announced in its 2002 spending
review. At the Sir William Dunn
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Cell action: Researchers around the UK are ramping up plans for human embryonic stem cell research, given the regulatory frame-
work that exists in the country compared with confusion and lack of support for such work in many other countries. (Photograph:
Science Photo Library.)
School of Pathology, for instance,
Herman Waldmann and Paul
Fairchild have set up a major
project, combining stem cell
expertise with immunology in
order to create generic cellular
therapies that can be made
palatable to the immune system
without having to resort to the
route of therapeutic cloning. In the
mouse model, they have turned
embryonic stem cells (ES cells)
into dendritic cells, a kind of
immune cell that can confer
tolerance of tissues derived from
the same cell line. 
Across the road, in the Zoology
Department, Chris Graham gets
£200,000 for fundamental
research into the technology of
reprogramming cells, that is,
taking specialised body cells and
‘turning back their clock’ to the
embryonic stage. Graham is
hoping to achieve this goal
without transferring the cell
nucleus into an egg (as it is done
in therapeutic and reproductive
cloning), using the cytoplasm (the
bulk liquid) of ES cells instead. In
the same department, Richard
Gardner investigates the
fundamental biology of
mammalian stem cells using mice.
He acknowledges that  “there is a
lot of stem cell research in Oxford,
but not enough coordination
between researchers”. 
While others are busy setting up
projects and institutes, the stem
cell laboratory at King’s College
London, can already work with its
very own human ES cell line, the
first to be created in the UK. The
laboratory had obtained one of
the first licences for creating such
cell lines, just after the House of
Lords had cleared the way for
research on human ES cells in
2002. Under UK law, all research
involving human embryos
depends on a specific licence




2003, Susan Pickering and
Stephen Minger reported their
success in establishing the first
human ES cell line. 
Last year, the Roslin Institute
near Edinburgh (the birth place of
Dolly the sheep), obtained the
HFEA’s permission to create




with its vast experience in the
embryology and cloning of
mammals is well positioned to
become a leader in medical
applications of human stem cells
as well. 
Another contender that is
poised to jump from animal to
human stem cell research is the
University of Newcastle upon
Tyne, where researchers around
Miodrag Stojkovic have already
isolated a novel human ES cell
line, which they are currently
characterizing in detail. A further
stem cell project at Newcastle, led
by Alison Murdoch at the
Newcastle Fertility Centre, is
being reviewed by the HFEA. It
addresses fundamental aspects of
nuclear transfer and
parthenogenesis. 
The opening of the world’s
first national stem cell bank
in May is expected to ensure
that stem cell lines and
information generated in the
UK will be accessible to the
entire scientific community
With so much research going
on in many different places, the
need for coordination on a
national level becomes more
pressing. The research councils
have already set up a series of
annual meetings of the grant
holders benefiting from the stem
cell initiative, the first of which
took place in July. 
Moreover, the opening of the
world’s first national stem cell
bank in May is expected to ensure
that stem cell lines and
information generated in the UK
will be accessible to the entire
scientific community. This
accessibility is an important
measure of quality control, as the
cell lines will be analysed and
characterized by many different
laboratories. The stem cell bank is
located at the National Institute
for Biological Standards and
Controls at Potter’s Bar, just
outside London. The first two
stem cell lines to be deposited
there were the ones developed at
King’s College and at Newcastle. 
Internationally, the UK’s MRC
has also fostered collaboration by
helping to set up the International
Stem Cell Forum together with
representatives from the US,
Canada, Australia, Japan,
Singapore, Israel, Germany,
France, The Netherlands, Finland,
Sweden, and the Juvenile
Diabetes Research Foundation
International. Chaired by MRC
chief executive Colin Blakemore,
the forum, which now also
includes Switzerland, has recently
announced the development of an
open access data registry for
stem cell research.
Thus it appears that stem cell
research in the UK has a flying
start, while many other leading
nations are still stuck in debates.
Ironically, the use of animals in
medical research is currently
much more under fire from hostile
sections of the public than the use
of human embryos. The world is
neatly split in two, with just under
half the world population living in
countries that allow the
production of human ES cells
(www.mbbnet.umn.edu/scmap.ht
ml). On closer inspection, the
balance looks a little less
promising, as the pro-stem cell
league includes populous but
poor countries such as China and
India. But with the US and most
European countries painting
themselves out of the picture and
leaving the creation of stem cell
lines to the likes of Israel and
South Korea, Britain looks likely to
be among the world leaders in this
field. And a recent decision to
allow, on a case-by-case basis,
the potential to screen human
embryos for the potential to be a
tissue match for existing siblings
in need of a cell donor because of
serious genetic disease, (see
following article) researchers and
doctors have another avenue of
research opening up to them in
the UK.
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